Blueprint Medicines

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases, blood disorders, and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Blueprint Medicines exceeds revenue expectations, eyes growth opportunities in 2023

Blueprint Medicines delivered strong financial results and outlined growth strategies for 2023, driven by AYVAKIT's performance.
The company faces uncertainties around label negotiation but benefits from strong market access and proactive market expansion efforts.
Opportunities lie in upcoming data presentations, CDK2 program updates, and capturing additional market share in the ISM segment.

Blueprint Medicines reports strong Q1 performance and growth opportunities

Blueprint Medicines showcased strong financial performance, a robust growth strategy, and promising pipeline advancements during the Q1 earnings call. While facing challenges in managing expenses and differentiating sales, the company is well-positioned to capitalize on opportunities in driving AYVAKYT sales and educating providers on SM treatment urgency.

Blueprint Medicines reports strong Q2 results and eyes market expansion

Blueprint Medicines demonstrated solid financial performance and positive market reception for AYVAKIT and BLU-222.
While facing challenges in operational execution and market competition, the company has opportunities for growth through portfolio expansion and market diversification.
Overall, Blueprint Medicines is well-positioned to capitalize on the success of AYVAKIT and the potential of BLU-222 in driving future growth and innovation.

Blueprint Medicines excels in Q3, eyes sustainable growth in 2024

Blueprint Medicines delivered strong Q3 results with a focus on sustainable revenue growth and pipeline advancement.
The company's strengths lie in AYVAKIT's market adoption, high patient retention rates, and promising pipeline assets.
Challenges include managing operating expenses, decreasing cash burn, and expanding market penetration for AYVAKIT.
Opportunities exist in developing new assets, presenting upcoming data, and achieving significant growth in 2024.

Blueprint Medicines reports robust 2023 performance and targets $2B peak sales

Blueprint Medicines' strong 2023 performance with AYVAKIT driving revenue growth sets the stage for continued success in 2024, aiming for peak sales exceeding $2 billion.
Strategic focus on expanding market presence, advancing pipeline assets, and maintaining financial discipline positions the company for sustained growth and profitability.
Opportunities lie in maximizing AYVAKIT's market potential, leveraging BLU-808 in inflammatory disorders, and exploring strategic growth avenues in cancer treatment.

Blueprint Medicines reports robust Q1 earnings, eyes strategic partnerships

Blueprint Medicines' strong financial performance, focus on sustainable growth, and strategic expansion into new therapeutic areas position the company for long-term success. Addressing challenges in physician adoption and patient prescription rates while leveraging growth opportunities in strategic partnerships and compound expansion will be crucial for future growth.

Blueprint Medicines excels in Q3 with robust AYVAKIT sales

Blueprint Medicines delivered strong revenue growth driven by AYVAKIT sales, showcasing high compliance and demand. With a focus on long-term growth and financial stability, the company aims to expand its impact with BLU-808 and maintain strong capital allocation priorities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Shares of Blueprint Medicines Corp. BPMC, -2.00% tumbled 11.7% in premarket trading on Tuesday after the company said a Phase 2 clinical trial evaluating Ayvakit in patients with non-advanced systemic mastocytosis, a rare disorder, met the primary and secondary endpoints. However, one Wall Street analyst said he is concerned about the change in the symptom score in the Phase 2 study, compared with the Phase 1 trial.

Blueprint's stock falls 11% after sharing new Phase 2 data for its rare-disease therapy

-- AYVAKIT showed a superior mean change in total symptom score (p=0.003), compared to placebo plus best available care -- -- Highly significant reductions across all objective measures of mast cell burden reinforce the disease modifying activity of AYVAKIT -- -- AYVAKIT had a favorable safety profile compared to the control arm, supporting potential for long-term treatment -- -- Plan to submit supplemental new drug application to FDA in fourth quarter of 2022 -- -- Blueprint Medicines to host investor conference call and webcast today at 8:00 a.m. ET -- CAMBRIDGE, Mass.

Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints

Guardant Health Inc

PALO ALTO, Calif., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, and Blueprint Medicines Corporation (Nasdaq: BPMC) announced today they are presenting new data demonstrating that the EGFR C797X mutation is the most common resistance mechanism to osimertinib therapy for patients with advanced non-small cell lung cancer (NSCLC). The results are being reported today at the International Association for the Study of Lung Cancer (IASLC

Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer

CAMBRIDGE, Mass. , Aug. 4, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective August 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 29,359 shares of its common stock and an aggregate of 14,675  restricted stock units (RSUs) to fourteen new employees under Blueprint Medicines' 2020 Inducement Plan.

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Blueprint Medicines' (BPMC) earnings and revenues fall shy of estimates for the second quarter of 2022. However, the stock is up.

Blueprint Medicines' (BPMC) Q2 Earnings & Revenues Miss Mark

Blueprint Medicines Corporation (NASDAQ:BPMC ) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - MD, Chief Medical Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Conference Call Participants Ernie Rodriguez - Cowen and Company Dane Leone - Raymond James Andrea Tan - Goldman Sachs Peter Lawson - Barclays Reni Benjamin - JMP Securities Eun Yang - Jefferies Brad Canino - Stifel David Nierengarten - Wedbush Securities Paul Jeng - Guggenheim Securities David Lebowitz - Citi Joel Beatty - Baird Matthew Biegler - Oppenheimer Operator Good morning. My name is Charlie, and I'll be your conference operator today.

Blueprint Medicines Corporation's (BPMC) CEO Kate Haviland on Q2 2022 Results - Earnings Call Transcript

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -20.18% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines (BPMC) Reports Q2 Loss, Lags Revenue Estimates

Royalty Pharma

-- Achieved $36.5 million in total revenues, including $28.5 million in AYVAKIT® (avapritinib) net product revenues representing 20 percent AYVAKIT revenue growth from Q1 2022 -- -- Plan to report topline data for registration-enabling PIONEER trial of AYVAKIT in non-advanced SM in August 2022 -- -- Licensed KIT exon 13 inhibitor to IDRx in exchange for a 15 percent Series A preferred equity investment, and the potential to receive up to $217.5 million in development, regulatory, and sales-based milestones and tiered percentage royalties -- -- Investor Day planned for November 1, 2022 in New York, NY -- CAMBRIDGE, Mass. , Aug. 2, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2022.

Blueprint Medicines Reports Second Quarter 2022 Results

CAMBRIDGE, Mass. , July 26, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

Blueprint Medicines to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022

-- Report highlights efforts to deliver sustainable value to patients and communities, foster a diverse and empowered workforce, and operate with exceptional integrity -- CAMBRIDGE, Mass. , July 14, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today published its first Corporate Responsibility Report, highlighting its long-standing commitment to deliver sustainable value to patients with cancer and blood disorders, as well as the communities in which it operates.

Blueprint Medicines Publishes Inaugural Corporate Responsibility Report

NEW YORK , July 13, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ: BPMC).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation - BPMC

New York, New York--(Newsfile Corp. - July 11, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ: BPMC). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Blueprint and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Blueprint Medicines Corporation - BPMC

Shares of Blueprint Medicines Corp. BPMC, -2.34% gained 3.3% in premarket trading on Thursday after the company announced a deal with investment firm Sixth Street and Royalty Pharma RPRX, -1.10% , which acquires pharmaceutical royalties, worth up to $1.2 billion. Sixth Street will pay $250 million upfront for future royalties for two products, up to $400 million in a senior secured credit facility, and $260 million in a potential credit facility to support any buy-side business opportunities.

Blueprint inks deal with Sixth Street, Royalty Pharma worth up to $1.2 billion

Strengthens balance sheet with significant non-dilutive, low-cost capital Expands ability to bring the promise of precision therapy to broad patient populations through internal R&D and strategic business development Propelled by global launches of AYVAKIT®/AYVAKYT® (avapritinib) and GAVRETO® (pralsetinib), and shared confidence in the important growth opportunity in systemic mastocytosis Blueprint Medicines will receive $575 million in total cash funded at close CAMBRIDGE, Mass. , June 30, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced strategic financing collaborations with Sixth Street and Royalty Pharma (NASDAQ: RPRX) for up to $1.25 billion, bringing significant non-dilutive, low-cost capital to drive innovation and growth.

Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma

Carnival

Deckers Outdoor

After last week's rally, markets have been under pressure this week, giving more credence to a bear market rally.

Wells Fargo Cuts Targets and Coverage on Carnival and More

CAMBRIDGE, Mass. , June 23, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Habib Dable to its board of directors.

Blueprint Medicines Appoints Habib Dable to its Board of Directors

Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved to treat rare cancer and other rare diseases, has seen strong uptake since approval. However, stiff competition remains a concern.

Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry

-- New analyses showing AYVAKIT® (avapritinib) significantly improved overall survival in advanced SM, when indirectly compared to real-world data for prior standard therapies, to be presented at EHA 2022 Congress -- -- Primary endpoint of PIONEER trial of AYVAKIT in non-advanced SM to be updated to mean change in total symptom score, previously a key secondary endpoint, based on U.S. FDA recommendation --  -- On track to report top-line registrational data from PIONEER trial in late summer 2022 -- -- Kate Haviland, Chief Executive Officer, to present at Jefferies Healthcare Conference today at 1:30 p.m. EDT -- CAMBRIDGE, Mass.

Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?

Why Is Blueprint Medicines (BPMC) Down 11.4% Since Last Earnings Report?

Affimed

OptimizeRx Corp

Here's why our roundtable thinks OptimizeRx, Affimed and Blueprint Medicines are all buys right now.

3 Small-Caps That Might Be Acquisition Candidates

Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.

Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark

Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Christy Rossi - Chief Operating Officer Philina Lee - Chief Commercial Officer Becker Hewes - MD, Chief Medical Officer Mike Landsittel - Chief Financial Officer Conference Call Participants Marc Frahm - Cowen Dane Leone - Raymond James Elizabeth - Goldman Sachs Reni Benjamin - JMP Securities Brad Canino - Stifel Andrew Berens - SVB Securities Mike Ulz - Morgan Stanley David Lebowitz - Citi Eun Yang - Jefferies Operator 00:03 Good morning. My name is Juan, and I will be your conference operator today.

Blueprint Medicines Corporation (BPMC) CEO Kate Haviland on Q1 2022 Results - Earnings Call Transcript

-- Achieved $23.8 million in AYVAKIT® (avapritinib) net product revenues, and $62.7 million in total revenues -- -- AYVAKYT® (avapritinib) launch in Germany underway following European Commission approval for advanced SM on March 25 -- -- First patients dosed in BLU-701, BLU-451, and BLU-222 clinical trials; trial cohort initiated for BLU-945 in combination with osimertinib -- -- On track to report topline data for registration-enabling PIONEER trial of AYVAKIT in non-advanced SM in late summer 2022 -- CAMBRIDGE, Mass., May 3, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31, 2022.

Blueprint Medicines Reports First Quarter 2022 Results

CAMBRIDGE, Mass. , April 26, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:30 a.m.

Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

-- Early dose escalation data show dose-dependent reductions in ctDNA and tumor burden -- -- Generally well-tolerated with most AEs Grade 1 or 2, supporting continued dose escalation -- -- Initiating SYMPHONY trial cohort to evaluate BLU-945 in combination with osimertinib -- -- Clinical trial supply agreement signed with AstraZeneca to provide osimertinib for combination development in ongoing BLU-945 and BLU-701 trials -- -- Blueprint Medicines to host investor conference call and webcast on Friday, April 8 at 2:00 pm ET -- CAMBRIDGE, Mass. , April 8, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced proof-of-concept data from the Phase 1/2 SYMPHONY clinical trial of BLU-945, an investigational precision therapy for advanced EGFR-mutant non-small cell lung cancer (NSCLC).

Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer

News for Blueprint Medicines Stock (BPMC)